- Report
- March 2024
- 183 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- January 2022
- 110 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Report
- August 2022
- 120 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Report
- November 2022
- 79 Pages
Global
From €1922EUR$2,000USD£1,650GBP
Haegarda is a market of drugs used to treat immune disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, and autoimmune diseases. They work by suppressing the body's immune response, which can help reduce inflammation and other symptoms associated with these conditions. Haegarda drugs are typically administered through injections or inhalers, and can be used to treat both acute and chronic conditions.
The Haegarda market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include Sanofi, GlaxoSmithKline, Merck, and Novartis. Other companies, such as CSL Behring, Teva Pharmaceuticals, and Mylan, also offer products in the Haegarda market. Show Less Read more